FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387207916> ?p ?o ?g. }

• W4387207916 endingPage "S108" @default.
• W4387207916 startingPage "S108" @default.
• W4387207916 abstract "Palliative radiotherapy (RT) is employed for patients with multiple myeloma to improve or prevent symptoms. However, the optimal dose fractionation is not well defined. The role of cytogenetics in informing RT warrants further study. We performed an institutional analysis of patients with multiple myeloma receiving palliative RT and assessed factors associated with local progression, with a focus on dose fractionation and cytogenetic abnormalities.We queried a prospectively maintained, departmental database for consecutive patients who received palliative RT for multiple myeloma at our institution from 2015 to 2020. Double- and triple-hit were defined as the presence of two and three high-risk cytogenetic abnormalities. RT dose fractionation data were extracted from the database. Follow-up imaging was used to evaluate for progression.A total of 239 patients with 362 treated lesions were included. Twenty-five patients (10.4%) with 39 lesions had double-hit cytogenetics, and 4 patients (1.7%) with 7 lesions were triple-hit. Patients had the following number of lesions treated with RT: 1 (156, 65.3%), 2 (53, 22.2%), 3 (17, 7.1%), or >3 (13, 5.4%). The most commonly targeted sites were spine (125, 34.5%), abdomen/pelvis (67, 18.5%), and lower extremity (53, 14.6%). Most lesions received doses of 20 Gy/5 fx (132, 36.5%), 8 Gy/1 fx (93, 25.7%), or 30 Gy/10 fx (48, 13.3%). RT equivalent dose in 2 Gray fractions (EQD2) was <2000 cGy for 126 lesions (34.8%) and ≥2000 cGy for 236 lesions (65.2%). At a median follow-up of 4.3 years, the risk of local progression on a per lesion basis at 1 and 4 years was 7.8% (95% CI: 5.5-11.1) and 13.4% (10.3-17.5), respectively. No cytogenetic abnormalities were correlated with local progression. Factors significant on univariate analysis included female sex [hazard ratio (HR): 1.94 (1.02-3.71), p = .045], LDH at diagnosis [HR per 10 units/liter: 1.04 (1.09-1.08), p = .016], and number of treated lesions [HR per lesion: 1.38 (1.02-1.89), p = .039]. These three covariates were included on multivariable analysis, and the only covariate to approach significance was number of treated lesions [HR for >3 versus 1: 2.43 (0.88-6.74), p = .059]. In the overall cohort, EQD2 did not impact risk of progression. Among those with >3 treated lesions, EQD2 ≥2000 cGy was associated with a significantly lower risk of progression [HR: 0.05 (0.01-0.23), p<.001]. Double- and triple-hit status were not correlated with progression. Median overall survival in all patients was 4.1 years versus 1.5 and 0.6 years in those with double- and triple-hit disease, respectively.In this large, institutional study of patients with multiple myeloma, palliative RT achieves durable long-term local control. Patients with high disease burden may be at increased risk of progression at treated sites. This group may benefit from an EQD ≥2000 cGy. Cytogenetics, including double- and triple-hit status, do not appear to influence RT response." @default.
• W4387207916 created "2023-09-30" @default.
• W4387207916 creator A5009318345 @default.
• W4387207916 creator A5020885025 @default.
• W4387207916 creator A5023100809 @default.
• W4387207916 creator A5033395766 @default.
• W4387207916 creator A5035077043 @default.
• W4387207916 creator A5035827527 @default.
• W4387207916 creator A5044847415 @default.
• W4387207916 creator A5053132558 @default.
• W4387207916 creator A5057465226 @default.
• W4387207916 creator A5074505099 @default.
• W4387207916 creator A5078705257 @default.
• W4387207916 creator A5081655908 @default.
• W4387207916 creator A5083513023 @default.
• W4387207916 creator A5092972841 @default.
• W4387207916 date "2023-10-01" @default.
• W4387207916 modified "2023-10-17" @default.
• W4387207916 title "Predictors of Local Control with Palliative Radiotherapy for Multiple Myeloma" @default.
• W4387207916 doi "https://doi.org/10.1016/j.ijrobp.2023.06.070" @default.
• W4387207916 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784284" @default.
• W4387207916 hasPublicationYear "2023" @default.
• W4387207916 type Work @default.
• W4387207916 citedByCount "0" @default.
• W4387207916 crossrefType "journal-article" @default.
• W4387207916 hasAuthorship W4387207916A5009318345 @default.
• W4387207916 hasAuthorship W4387207916A5020885025 @default.
• W4387207916 hasAuthorship W4387207916A5023100809 @default.
• W4387207916 hasAuthorship W4387207916A5033395766 @default.
• W4387207916 hasAuthorship W4387207916A5035077043 @default.
• W4387207916 hasAuthorship W4387207916A5035827527 @default.
• W4387207916 hasAuthorship W4387207916A5044847415 @default.
• W4387207916 hasAuthorship W4387207916A5053132558 @default.
• W4387207916 hasAuthorship W4387207916A5057465226 @default.
• W4387207916 hasAuthorship W4387207916A5074505099 @default.
• W4387207916 hasAuthorship W4387207916A5078705257 @default.
• W4387207916 hasAuthorship W4387207916A5081655908 @default.
• W4387207916 hasAuthorship W4387207916A5083513023 @default.
• W4387207916 hasAuthorship W4387207916A5092972841 @default.
• W4387207916 hasConcept C126322002 @default.
• W4387207916 hasConcept C126838900 @default.
• W4387207916 hasConcept C159110408 @default.
• W4387207916 hasConcept C2776364478 @default.
• W4387207916 hasConcept C2778357063 @default.
• W4387207916 hasConcept C2779983558 @default.
• W4387207916 hasConcept C2989005 @default.
• W4387207916 hasConcept C2994186709 @default.
• W4387207916 hasConcept C509974204 @default.
• W4387207916 hasConcept C71924100 @default.
• W4387207916 hasConceptScore W4387207916C126322002 @default.
• W4387207916 hasConceptScore W4387207916C126838900 @default.
• W4387207916 hasConceptScore W4387207916C159110408 @default.
• W4387207916 hasConceptScore W4387207916C2776364478 @default.
• W4387207916 hasConceptScore W4387207916C2778357063 @default.
• W4387207916 hasConceptScore W4387207916C2779983558 @default.
• W4387207916 hasConceptScore W4387207916C2989005 @default.
• W4387207916 hasConceptScore W4387207916C2994186709 @default.
• W4387207916 hasConceptScore W4387207916C509974204 @default.
• W4387207916 hasConceptScore W4387207916C71924100 @default.
• W4387207916 hasIssue "2" @default.
• W4387207916 hasLocation W43872079161 @default.
• W4387207916 hasLocation W43872079162 @default.
• W4387207916 hasOpenAccess W4387207916 @default.
• W4387207916 hasPrimaryLocation W43872079161 @default.
• W4387207916 hasRelatedWork W1185770558 @default.
• W4387207916 hasRelatedWork W1966902899 @default.
• W4387207916 hasRelatedWork W2062678678 @default.
• W4387207916 hasRelatedWork W2072399844 @default.
• W4387207916 hasRelatedWork W2091515907 @default.
• W4387207916 hasRelatedWork W2162089832 @default.
• W4387207916 hasRelatedWork W2763816647 @default.
• W4387207916 hasRelatedWork W2894754340 @default.
• W4387207916 hasRelatedWork W2895323313 @default.
• W4387207916 hasRelatedWork W4386117203 @default.
• W4387207916 hasVolume "117" @default.
• W4387207916 isParatext "false" @default.
• W4387207916 isRetracted "false" @default.
• W4387207916 workType "article" @default.